Display options
Cite
Gilliaux Q, Faugeras L, Martinet JP, et al. Incidence and Prognosis of Biliary Tract and Gallbladder Cancers in a Belgian Academic Hospital. J Gastrointest Cancer. 2020;52(3):1003-1009doi: 10.1007/s12029-020-00526-5.
Gilliaux, Q., Faugeras, L., Martinet, J. P., De Ronde, T., Badaoui, A., Bertrand, C., Dili, A., Delos, M., Jamart, J., Baily, A., & D'Hondt, L. (2021). Incidence and Prognosis of Biliary Tract and Gallbladder Cancers in a Belgian Academic Hospital. Journal of gastrointestinal cancer, 52(3), 1003-1009. https://doi.org/10.1007/s12029-020-00526-5
Gilliaux, Quentin, et al. "Incidence and Prognosis of Biliary Tract and Gallbladder Cancers in a Belgian Academic Hospital." Journal of gastrointestinal cancer vol. 52,3 (2021): 1003-1009. doi: https://doi.org/10.1007/s12029-020-00526-5
Gilliaux Q, Faugeras L, Martinet JP, De Ronde T, Badaoui A, Bertrand C, Dili A, Delos M, Jamart J, Baily A, D'Hondt L. Incidence and Prognosis of Biliary Tract and Gallbladder Cancers in a Belgian Academic Hospital. J Gastrointest Cancer. 2021 Sep;52(3):1003-1009. doi: 10.1007/s12029-020-00526-5. Epub 2020 Sep 28. PMID: 32984916.
Copy Download .nbib Format: NLM
Share it on

J Gastrointest Cancer. 2021 Sep;52(3):1003-1009. doi: 10.1007/s12029-020-00526-5. Epub 2020 Sep 28.

Incidence and Prognosis of Biliary Tract and Gallbladder Cancers in a Belgian Academic Hospital.

Journal of gastrointestinal cancer

Quentin Gilliaux, Laurence Faugeras, Jean-Paul Martinet, Thierry De Ronde, Abdenor Badaoui, Claude Bertrand, Alexandra Dili, Monique Delos, Jacques Jamart, Axel Baily, Lionel D'Hondt

Affiliations

  1. Department of Oncology, CHU UCL Namur, Site Godinne, Yvoir, Belgium. [email protected].
  2. Department of Oncology, CHU UCL Namur, Site Godinne, Yvoir, Belgium.
  3. Department of Gastroenterology, CHU UCL Namur, Site Godinne, Yvoir, Belgium.
  4. Department of Surgery, CHU UCL Namur, Site Godinne, Yvoir, Belgium.
  5. Department of Anatomopathology, CHU UCL Namur, Site Godinne, Yvoir, Belgium.
  6. Scientific Support Unit, CHU UCL Namur, Site Godinne, Yvoir, Belgium.

PMID: 32984916 DOI: 10.1007/s12029-020-00526-5

Abstract

BACKGROUND: Biliary tract and gallbladder cancers are rare tumors with a poor prognosis (except the ampulla type). The evolution of hepatobiliary cancer incidence varies widely around the world. According to the Belgian Cancer Registry, the number of hepatobiliary cancers has increased every year since 2004.

MATERIALS AND METHODS: This retrospective study included patients diagnosed with cholangiocarcinoma, ampulla cancer, or gallbladder cancer at the university hospital, CHU UCL, Godinne site, in Namur, Belgium, between 1997 and 2017. The evolution of cancer incidence was evaluated with the Mann-Kendall method, by analyzing 7 consecutive 3-year periods. We calculated survival with the Kaplan-Meier method, and we determined prognostic factors with the log-rank test and Cox models.

RESULTS: Between 1997 and 2017, we included 128 patients that were newly diagnosed in our center. According to the Mann-Kendall test, the evolution of the incidence of these cancers in our hospital increased significantly over the study period (Sen's slope = 7; p = 0.003). The 1-year overall survival was 53.0 ± 4.7%. Poor prognostic factors included age, cancer stage, local cancer extension, and metastatic disease. The independent prognostic factors of survival were age (p = 0.002), ampulla cancer (p < 0.001), and metastatic disease (p < 0.001).

CONCLUSIONS: We found that the incidence of biliary tract and gallbladder cancers increased over a period of 20 years in our center. Further investigations are needed to determine the reasons for this increase. Although new therapies are emerging, the prognosis remains poor for these cancers. Determining risk factors might promote the development of preventive approaches.

© 2020. Springer Science+Business Media, LLC, part of Springer Nature.

Keywords: Belgium; Cholangiocarcinoma; Epidemiology; Risk factor; Survival

References

  1. Petrick JL, Braunlin M, Laversanne M, Valery PC, Bray F, McGlynn KA. International trends in liver cancer incidence, overall and by histologic subtype, 1978-2007. Int J Cancer. 2016;139(7):1534–45. - PubMed
  2. Minicozzi P, Cassetti T, Vener C, Sant M. Analysis of incidence, mortality and survival for pancreatic and biliary tract cancers across Europe, with assessment of influence of revised European age standardisation on estimates. Cancer Epidemiol. 2018;55:52–60. - PubMed
  3. Saha SK, Zhu AX, Fuchs CS, Brooks GA. Forty-year trends in Cholangiocarcinoma incidence in the U.S.: intrahepatic disease on the rise. Oncologist. 2016;21(5):594–9. - PubMed
  4. Belgian Cancer Registry. Available at: https://kankerregister.org/Figures (Accessed Aug 25, 2020). - PubMed
  5. Squadroni M, Tondulli L, Gatta G, Mosconi S, Beretta G, Labianca R. Cholangiocarcinoma. Crit Rev Oncol Hematol. 2017;116:11–31. - PubMed
  6. Sithithaworn P, Yongvanit P, Duenngai K, Kiatsopit N, Pairojkul C. Roles of liver fluke infection as risk factor for cholangiocarcinoma. J Hepatobiliary Pancreat Sci. 2014;21(5):301–8. - PubMed
  7. Kim TS, Pak JH, Kim JB, Bahk YY. Clonorchis sinensis, an oriental liver fluke, as a human biological agent of cholangiocarcinoma: a brief review. BMB Rep. 2016;49(11):590–7 Review. - PubMed
  8. Labib PL, Goodchild G, Pereira SP. Molecular pathogenesis of cholangiocarcinoma. BMC Cancer. 2019;19(1):185. - PubMed
  9. Khan SA, Tavolari S, Brandi G. Cholangiocarcinoma: epidemiology and risk factors. Liver Int. 2019;39(Suppl 1):19–31. https://doi.org/10.1111/liv.14095 . - PubMed
  10. Walter D, Ferstl P, Waidmann O, Trojan J, Hartmann S, Schnitzbauer AA, et al. Cholangiocarcinoma in Germany: epidemiologic trends and impact of misclassification. Liver Int. 2019;39(2):316–23. - PubMed
  11. Belgian Health Interview Survey. Available at: https://hisia.wiv-isp.be/SitePages/Home.aspx (Accessed sept 8, 2019). - PubMed
  12. Vaes B, Ruelens C, Saikali S, Smets A, Henrard S, Renard F, et al. Estimating the prevalence of diabetes mellitus and thyroid disorders using medication data in Flanders, Belgium. Eur J Pub Health. 2018;28(1):193–8. - PubMed
  13. Gatta G, Capocaccia R, Botta L, Mallone S, De Angelis R, Ardanaz E, et al. RARECAREnet working group. Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet-a population-based study. Lancet Oncol. 2017;18(8):1022–39. - PubMed
  14. Bridgewater J, Lopes A, Wasan H, Malka D, Jensen L, Okusaka T, et al. Prognostic factors for progression-free and overall survival in advanced biliary tract cancer. Ann Oncol. 2016;27(1):134–40. - PubMed

Publication Types